The future of immune checkpoint therapy
Science2015Vol. 348(6230), pp. 56–61
Citations Over TimeTop 1% of 2015 papers
Abstract
Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led to important clinical advances and provided a new weapon against cancer. This therapy has elicited durable clinical responses and, in a fraction of patients, long-term remissions where patients exhibit no clinical signs of cancer for many years. The way forward for this class of novel agents lies in our ability to understand human immune responses in the tumor microenvironment. This will provide valuable information regarding the dynamic nature of the immune response and regulation of additional pathways that will need to be targeted through combination therapies to provide survival benefit for greater numbers of patients.
Related Papers
- → Probiotics Mechanism of Action on Immune Cells and Beneficial Effects on Human Health(2023)724 cited
- → Immunotherapy and tumor microenvironment(2015)303 cited
- → Role of the tumor immune microenvironment in tumor immunotherapy (Review)(2021)41 cited
- → Immunometabolism in the tumor microenvironment and its related research progress(2022)28 cited
- Research Progress of Immune Cell Function in Patients with Recurrent Genital Herpes(2012)